NasdaqGS:RGENLife Sciences
How Investors Are Reacting To Repligen (RGEN) Earnings Beat Paired With Cautious 2026 Guidance
In February 2026, Repligen Corporation reported that fourth-quarter 2025 revenue rose to US$197.91 million from US$167.55 million a year earlier, swinging from a net loss to net income of US$13.29 million and turning prior per-share losses into positive earnings.
Alongside this stronger profitability, the company issued relatively cautious 2026 guidance for revenue of US$810 million to US$840 million and diluted earnings per share of US$1.93 to US$2.01, which contrasted with its recent...